Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
KU Leuven
With
Jules Bordet Institute
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
2. At least 18 years of age at the time of signing the Informed Consent Form (ICF)
3. ECOG from 0 to 2
4. Patient with stage IV ILC, either de novo or after prior (curative) treatment for early ILC. Histological subtype confirmed on primary tumor or on metastatic tissue. Patients that are diagnosed with stage IV breast cancer that have a mixed ILC/IBC-NST histology of the primary tumor (mixed histology within the same primary lesion) will also be able to participate and will be analyzed in an exploratory cohort.
5. Confirmation of hormone receptor positive (HR+)/HER2- disease either on new biopsy or archival tissue (e.g. primary tumor)
6. Multifocal or bilateral disease is allowed if all evaluated foci present with HR+/HER2- ILC
7. Starting first line of treatment for metastatic ILC
You may not be if
1. Presence of a contraindication to perform WB-DWI/MRI
2. Presence of severe claustrophobia
3. Presence of a contraindication to use IV contrast for CT or PET/CT (e.g. allergy, severe renal failure) in case a non-contrast PET/CT cannot be performed
4. Patients considered to have oligometastatic disease who are expected to undergo locoregional treatment
5. Presence of other malignancies in recent medical history (\<5 years)
6. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive
7. Adults who are the subject of a legal protection measure or who are unable to express their consent.
